 | Up a level |
Panje, Cédric; Lupatsch, J; Barbier, M; Pardo, E; Lorez, M; Dedes, K J; Aebersold, D. M.; Plasswilm, Ludwig; Gautschi, O.; Schwenkglenks, M. (2020). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Annals of oncology, 31(4), pp. 501-506. Oxford University Press 10.1016/j.annonc.2020.01.007
